IFNL3 and hepatocellular carcinoma: Another limitation is that we did not evaluate the effect of IL28B gene polymorphisms on developing different ad-verse effects of DAAs especially liver decompensation and hepatocellular carcinoma and whether IL-12 affected the incidence of adverse effects related to DAAs.